


59. Nektar Therapeutics. A multicentre, open-label, randomized, phase 2 study to evaluate the efficacy and safety of NKT-102 versus irinotecan in patients with second-line, irinotecan-naive, KRAS-mutant, metastatic colorectal cancer (mCRC). Clinical Trials Identifier: NCT03085575.


